Three early Christmas presents… but what will be the New Year’s resolutions?

November was an amazing month for the myeloma community: FDA approval for three new therapies. The very good, but challenging problem is how to integrate and use these three new agents within the recommended treatment protocols for myeloma patients.

First monoclonal antibody approved

What to expect from this year’s ASH: a preview

This year’s Annual Meeting of the American Society of Hematology (ASH) will be held at the Orange County Convention Center in Orlando, FL, December 5-8.

MRD testing in myeloma takes center stage

Last week’s 4th Annual ESLHO (European Scientific foundation of Laboratory Hemato Oncology) Symposium in Zurich, Switzerland was the first ever dedicated exclusively to examining “New Developments in MRD Diagnostics.” The two-day event provided a comprehensive review of the current status of MRD (minimal residual disease) testing and future optio

Is it the end of the American diet? The bad and the good about food, cancer, and longevity

This past week has been full of controversy about the dangers of bacon and processed meats.

China update: renewed friendships and new collaborations

The International Myeloma Foundation (IMF) team—Susie Novis, IMF President; Lisa Paik, Senior Vice President, Clinical Education & Research Initiatives; Dan Navid, Vice President, Global Affairs; and myself— just returned from Beijing, China, where we participated in what will be the annual meetings of the Chinese Myeloma Committee.

Pages